ACLARION, INC. Deferred Offering Costs
ACLARION, INC. (ACON) had Deferred Offering Costs of $1.09 million as of 2023-12-31, per its 10-K filed 2025-04-09.
Financial Statements › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredOfferingCosts · last filed 2025-04-09
- 2023-12-31: Deferred Offering Costs $1.09M; Deferred Offering Costs as first filed $204.65K.
- 2022-09-30: Deferred Offering Costs $0.00.
- 2022-04-30: Deferred Offering Costs $1.50M.
| Period end | Deferred Offering Costs | Deferred Offering Costs as first filed |
|---|---|---|
| 2023-12-31 | $1.09M 10-K · filed 2025-04-09 | $204.65K 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | |
| 2022-04-30 | $1.50M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |